Attachment sites and neutralising epitopes of hepatitis B virus

Minerva Gastroenterologica e Dietologica

Volumn 52, Issue 1, 2006, Pages 3-21

  Glebe, D ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

HBV; Infection models; Receptor; Tupaia belangeri; Viral attachment

Indexed keywords

EPITOPE; LIPOPEPTIDE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN PRES1; PROTEIN PRES2; UNCLASSIFIED DRUG;

GENOME ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL; NONHUMAN; PROTEIN DOMAIN; REVIEW; SCANDENTIA; VIRAL PHENOMENA AND FUNCTIONS;

EPITOPES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; PROTEIN PRECURSORS; RECEPTORS, VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 33646356716     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-33.
2. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol 1984;52:396-402.
3. Schmitt S, Glebe D, Alving K, Tolle TK, Linder M, Geyer H et al. Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus. J Biol Chem 1999;274:11945-57.
4. Tolle TK, Glebe D, Linder M, Linder D, Schmitt S, Geyer R et al. Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J Virol 1998;72:9978-85.
5. Schmitt S, Glebe D, Tolle TK, Lochnit G, Linder D, Geyer R et al. Structure of pre-S2 N- and O-linked glycans in surface proteins from different genotypes of hepatitis B virus. J Gen Virol 2004;85:2045-53.
6. Bruss V. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. J Virol 1997;71:9350-7.
7. Ponsel D, Bruss V. Mapping of amino acid side chains on the surface of hepatitis B virus capsids required for envelopment and virion formation. J Virol 2003;77:416-22.
8. Bruss V, Lu X, Thomssen R, Gerlich WH. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J 1994;13:2273-9.
9. Lambert C, Prange R. Chaperone action in the post-translational topological reorientation of the hepatitis B virus large envelope protein: implications for translocational regulation. Proc Natl Acad Sci U S A 2003;100:5199-204.
10. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987;84:1005-9.
11. Shih CH, Li LS, Roychoudhury S, Ho MH. In vitro propagation of human hepatitis B virus in a rat hepatoma cell line. Proc Natl Acad Sci U S A 1989;86:6323-7.
12. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A 2002;99:13825-30.
13. Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol 1995;69:6158-69.
14. Barker LF, Chisari FV, McGrath PP, Dalgard DW, Kirschstein RL, Almeida JD et al. Transmission of type B viral hepatitis to chimpanzees. J Infect Dis 1973;127:648-62.
15. Dienstag JL, Popper H, Purcell RH. The pathology of viral hepatitis types A and B in chimpanzees. A comparison. Am J Pathol 1976;85:131-48.
16. Popper H, Dienstag JL, Feinstone SM, Alter HJ, Purcell RH. The pathology of viral hepatitis in chimpanzees. Virchows Arch A Pathol Anat Histol 1980;387:91-106.
17. Pillot J, Poynard T, Elias A, Maillard J, Lazizi Y, Brancer M et al. Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine. Vaccine 1995;13:289-94.
18. Deinhardt F. Hepatitis in primates. Adv Virus Res 1976;20:113-57.
19. Alter HJ, Purcell RH, Gerin JL, London WT, Kaplan PM, McAuliffe VJ et al. Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen. Infect Immun 1977;16:928-33.
20. Berthelot P, Courouce AM, Eyquem A, Feldmann G, Jacob J, Ravisse P et al. Hepatitis B vaccine safety monitoring in the chimpanzee: interpretation of results. J Med Primatol 1984;13:119-33.
21. Ohmura T, Ohmizu A, Sumi A, Ohtani W, Uemura Y, Arimura H et al. Properties of recombinant hepatitis B vaccine. Biochem Biophys Res Commun 1987;149:1172-8.
22. Will H, Cattaneo R, Koch HG, Darai G, Schaller H, Schellekens H et al. Cloned HBV DNA causes hepatitis in chimpanzees. Nature 1982;299:740-2.
23. Lanford RE, Chavez D, Brasky KM, Burns RB 3rd, Rico-Hesse R. Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci U S A 1998;95:5757-61.
24. Lanford RE, Chavez D, Barrera A, Brasky KM. An infectious clone of woolly monkey hepatitis B virus. J Virol 2003;77:7814-9.
25. Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001;33:981-8.
26. Dandri M, Burda MR, Zuckerman DM, Wursthorn K, Matschl U, Pollok JM et al. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol 2005;42:54-60.
27. Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, Eren R et al. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 1999;29:553-62.
28. Brown JJ, Parashar B, Moshage H, Tanaka KE, Engelhardt D, Rabbani E et al. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. Hepatology 2000;31:173-81.
29. Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, Imamura M et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005;42:1046-54.
30. Li Q, Ding M, Wang H. [The infection of hepatitis D virus in adult tupaia]. Zhonghua Yi Xue Za Zhi 1995;75:611-3, 639-40. Chinese.
31. Walter E, Keist R, Niederost B, Pult I, Blum HE. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 1996;24:1-5.
32. Yan RQ, Su JJ, Huang DR, Gan YC, Yang C, Huang GH. Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus. J Cancer Res Clin Oncol 1996;122:283-8.
33. Martin RD. Primate origin and evolution: a phylogenetic reconstruction. London: Chapman Hall; 1990.
34. Schmitz J, Ohme M, Zischler H. The complete mitochondrial genome of Tupaia belangeri and the phylogenetic affiliation of scandentia to other eutherian orders. Mol Biol Evol 2000;17:1334-43.
35. Nishihara H, Terai Y, Okada N. Characterization of novel Alu- and tRNA-related SINEs from the tree shrew and evolutionary implications of their origins. Mol Biol Evol 2002;19:1964-72.
36. Fuchs E, Schumacher M. Psychosocial stress affects pineal function in the tree shrew (Tupaia belangeri). Physiol Behav 1990;47:713-7.
37. Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 1988;62:4136-43.
38. Runge DM, Runge D, Dorko K, Pisarov LA, Leckel K, Kostrubsky VE et al. Epidermal growth factor- and hepatocyte growth factor-receptor activity in serum-free cultures of human hepatocytes. J Hepatol 1999;30:265-74.
39. Gripon P, Diot C, Guguen-Guillouzo C. Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology 1993;192:534-40.
40. Galle PR, Hagelstein J, Kommerell B, Volkmann M, Schranz P, Zentgraf H. in vitro experimental infection of primary human hepatocytes with hepatitis B virus. Gastroenterology 1994;106:664-73.
41. Mabit H, Vons C, Dubanchet S, Capel F, Franco D, Petit MA. Primary cultured normal human hepatocytes for hepatitis B virus receptor studies. J Hepatol 1996;24:403-12.
42. Schulze-Bergkamen H, Untergasser A, Dax A, Vogel H, Buchler P, Klar E et al. Primary human hepatocytes-a valuable tool for investigation of apoptosis and hepatitis B virus infection. J Hepatol 2003;38:736-44.
43. Köck J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsacker F. Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 2001;75:5084-9.
44. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 2003;77:9511-21.
45. Glebe D, Urban S, Knoop EV, Cag N, Krass P, Grun S et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005;129:234-45.
46. Köck J, Glebe D. Hepatitis B virus infection of primary Tupaia hepatocytes. In: Von Weizsäcker F, Roggendorf M, editors. Models of viral hepatitis. Basel: Karger; 2005. Vol. 25, p. 96-105.
47. Fowler E, Raab-Traub N, Hester S. Purification of biologically active Epstein-Barr virus by affinity chromatography and non-ionic density gradient centrifugation. J Virol Methods 1985;11:59-74.
48. Glebe D, Gerlich WH. Study of the endocytosis and intracellular localization of subviral particles of hepatitis B virus in primary hepatocytes. Methods Mol Med 2004;96:143-51.
49. Köck J, Baumert TF, Delaney WE, Blum HE, von Weizsacker F. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology 2003;38:1410-8.
50. Baumert TF, Yang C, Schurmann P, Kock J, Ziegler C, Grullich C et al. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology 2005;41:247-56.
51. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979;282:615-6.
52. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980;209:497-9.
53. Bchini R, Capel F, Dauguet C, Dubanchet S, Petit MA. In vitro infection of human hepatoma (HepG2) cells with hepatitis B virus. J Virol 1990;64:3025-32.
54. Mabit H, Dubanchet S, Capel F, Dauguet C, Petit MA. In vitro infection of human hepatoma cells (HepG2) with hepatitis B virus (HBV): spontaneous selection of a stable HBV surface antigen-producing HepG2 cell line containing integrated HBV DNA sequences. J Gen Virol 1994;75 (Pt 10):2681-9.
55. Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986;46:429-36.
56. Petit MA, Dubanchet S, Capel F, Voet P, Dauguet C, Hauser P. HepG2 cell binding activities of different hepatitis B virus isolates: inhibitory effect of anti-HBs and anti-preS1(21-47). Virology 1991;180:483-91.
57. Qiao M, Macnaughton TB, Gowans EJ. Adsorption and penetration of hepatitis B virus in a nonpermissive cell line. Virology 1994;201:356-63.
58. Treichel U, Meyer zum Buschenfelde KH, Stockert RJ, Poralla T, Gerken G. The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol 1994;75 (Pt 11):3021-9.
59. Treichel U, Meyer zum Buschenfelde KH, Dienes HP, Gerken G. Receptor-mediated entry of hepatitis B virus particles into liver cells. Arch Virol 1997;142:493-8.
60. De Falco S, Ruvoletto MG, Verdoliva A, Ruvo M, Raucci A, Marino M et al. Cloning and expression of a novel hepatitis B virus-binding protein from HepG2 cells. J Biol Chem 2001;276:36613-23.
61. Lu X, Block T. Study of the early steps of the hepatitis B virus life cycle. Int J Med Sci 2004;1:21-33.
62. Berting A, Fischer C, Schaefer S, Garten W, Klenk HD, Gerlich WH. Hemifusion activity of a chimeric influenza virus hemagglutinin with a putative fusion peptide from hepatitis B virus. Virus Res 2000;68:35-49.
63. Chojnacki J, Anderson DA, Grgacic EV. A hydrophobic domain in the large envelope protein is essential for fusion of duck hepatitis B virus at the late endosome. J Virol 2005;79:14945-55.
64. Lu X, Block TM, Gerlich WH. Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line. J Virol 1996;70:2277-85.
65. Paran N, Geiger B, Shaul Y. HBV infection of cell culture: evidence for multivalent and cooperative attachment. EMBO J 2001;20:4443-53.
66. Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT, Davidson NE. Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 1997;272:32260-6.
67. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002;99:15655-60.
68. Jaoude GA, Sureau C. Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus. J Virol 2005;79:10460-6.
69. Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005;79:1613-22.
70. Pontisso P, Ruvoletto MG, Gerlich WH, Heermann KH, Bardini R, Alberti A. Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology 1989;173:522-30.
71. Neurath AR, Strick N, Sproul P, Ralph HE, Valinsky J. Detection of receptors for hepatitis B virus on cells of extrahepatic origin. Virology 1990;176:448-57.
72. Neurath AR, Strick N. Antigenic mimicry of an immunoglobulin A epitope by a hepatitis B virus cell attachment site. Virology 1990;178:631-4.
73. Pontisso P, Ruvoletto MG, Tiribelli C, Gerlich WH, Ruol A, Alberti A. The preS1 domain of hepatitis B virus and IgA cross-react in their binding to the hepatocyte surface. J Gen Virol 1992;73 (Pt 8):2041-5.
74. Dash S, Rao KV, Panda SK. Receptor for pre-S1(21-47) component of hepatitis B virus on the liver cell: role in virus cell interaction. J Med Virol 1992;37:116-21.
75. Neurath AR, Strick N, Sproul P. Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exp Med 1992;175:461-9.
76. Neurath AR, Strick N, Li YY. Cells transfected with human interleukin 6 cDNA acquire binding sites for the hepatitis B virus envelope protein. J Exp Med 1992;176:1561-9.
77. Remold-O'Donnell E. The ovalbumin family of serpin proteins. FEBS Lett 1993;315:105-8.
78. Pontisso P, Calabrese F, Benvegnu L, Lise M, Belluco C, Ruvoletto MG et al. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer 2004;90:833-7.
79. Ruvoletto MG, Tono N, Carollo D, Vilei T, Trentin L, Muraca M et al. Surface expression of squamous cell carcinoma antigen (SCCA) can be increased by the preS1(21-47) sequence of hepatitis B virus. J Gen Virol 2004;85:621-4.
80. Ryu CJ, Cho DY, Gripon P, Kim HS, Guguen-Guillouzo C, Hong HJ. An 80-kilodalton protein that binds to the pre-S1 domain of hepatitis B virus. J Virol 2000;74:110-6.
81. Petit MA, Capel F, Dubanchet S, Mabit H. PreS1-specific binding proteins as potential receptors for hepatitis B virus in human hepatocytes. Virology 1992;187:211-22.
82. Duclos-Vallee JC, Capel F, Mabit H, Petit MA. Phosphorylation of the hepatitis B virus core protein by glyceraldehyde-3-phosphate dehydrogenase protein kinase activity. J Gen Virol 1998;79 (Pt 7):1665-70.
83. Budkowska A, Quan C, Groh F, Bedossa P, Dubreuil P, Bouvet JP et al. Hepatitis B virus (HBV) binding factor in human serum: candidate for a soluble form of hepatocyte HBV receptor. J Virol 1993;67:4316-22.
84. Budkowska A, Maillard P, Theret N, Groh F, Possehl C, Topilko A et al. Activation of the envelope proteins by a metalloproteinase enables attachment and entry of the hepatitis B virus into T-lymphocyte. Virology 1997;237:10-22.
85. Stoll-Becker S, Repp R, Glebe D, Schaefer S, Kreuder J, Kann M et al. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. J Virol 1997;71:5399-407.
86. Harvey TJ, Macnaughton TB, Park DS, Gowans EJ. A cellular protein which binds hepatitis B virus but not hepatitis B surface antigen. J Gen Virol 1999;80 (Pt 3):607-15.
87. Li D, Wang XZ, Ding J, Yu JP. NACA as a potential cellular target of hepatitis B virus preS1 protein. Dig Dis Sci 2005;50:1156-60.
88. Owada T, Matsubayashi K, Sakata H, Ihara H, Sato S, Ikebuchi K et al. Interaction between desialylated hepatitis B virus and asialoglycoprotein receptor on hepatocytes may be indispensable for viral binding and entry. J Viral Hepat 2006;13:11-8.
89. Machida A, Kishimoto S, Ohnuma H, Baba K, Ito Y, Miyamoto H et al. A polypeptide containing 55 amino acid residues coded by the pre-S region of hepatitis B virus deoxyribonucleic acid bears the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology 1984;86:910-8.
90. Trevisan A, Gudat F, Guggenheim R, Krey G, Durmuller U, Luond G et al. Demonstration of albumin receptors on isolated human hepatocytes by light and scanning electron microscopy. Hepatology 1982;2:832-5.
91. Pontisso P, Petit MA, Bankowski MJ, Peeples ME. Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. J Virol 1989;63:1981-8.
92. Dash S, Rao KV, Joshi B, Nayak NC, Panda SK. Significance of natural polymerized albumin and its receptor in hepatitis B infection of hepatocytes. Hepatology 1991;13:134-42.
93. Krone B, Lenz A, Heermann KH, Seifer M, Lu XY, Gerlich WH. Interaction between hepatitis B surface proteins and monomeric human serum albumin. Hepatology 1990;11:1050-6.
94. Sobotta D, Sominskaya I, Jansons J, Meisel H, Schmitt S, Heermann KH et al. Mapping of immunodominant B-cell epitopes and the human serum albumin- binding site in natural hepatitis B virus surface antigen of defined genosubtype. J Gen Virol 2000;81:369-78.
95. Neurath AR, Kent SB, Parker K, Prince AM, Strick N, Brotman B et al. Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine 1986;4:35-7.
96. Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A et al. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci U S A 1986;83:9174-8.
97. Franco A, Paroli M, Testa U, Benvenuto R, Peschle C, Balsano F et al. Transferrin receptor mediates uptake and presentation of hepatitis B envelope antigen by T lymphocytes. J Exp Med 1992;175:1195-205.
98. Budkowska A, Bedossa P, Groh F, Louise A, Pillot J. Fibronectin of human liver sinusoids binds hepatitis B virus: identification by an anti-idiotypic antibody bearing the internal image of the pre-S2 domain. J Virol 1995;69:840-8.
99. Mehdi H, Kaplan MJ, Anlar FY, Yang X, Bayer R, Sutherland K et al. Hepatitis B virus surface antigen binds to apolipoprotein H. J Virol 1994;68:2415-24.
100. Mehdi H, Yang X, Peeples ME. An altered form of apolipoprotein H binds hepatitis B virus surface antigen most efficiently. Virology 1996;217:58-66.
101. Lee NS, Brewer HB Jr, Osborne JC Jr. beta 2-Glycoprotein I. Molecular properties of an unusual apolipoprotein, apolipoprotein H. J Biol Chem 1983;258:4765-70.
102. Hertogs K, Leenders WP, Depla E, De Bruin WC, Meheus L, Raymackers J et al. Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope protein. Virology 1993;197:549-57.
103. Gong ZJ, De Meyer S, van Pelt J, Hertogs K, Depla E, Soumillion A et al. Transfection of a rat hepatoma cell line with a construct expressing human liver annexin V confers susceptibility to hepatitis B virus infection. Hepatology 1999;29:576-84.
104. Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J Virol 1999;73:2052-7.
105. Bruss V, Hagelstein J, Gerhardt E, Galle PR. Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity. Virology 1996;218:396-9.
106. Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 1995;213:292-9.
107. Urban S, Gripon P. Inhibition of duck hepatitis B virus infection by a myristoylated pre-S peptide of the large viral surface protein. J Virol 2002;76:1986-90.
108. Hogle JM. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu Rev Microbiol 2002;56:677-702.
109. Liemann S, Chandran K, Baker TS, Nibert ML, Harrison SC. Structure of the reovirus membrane-penetration protein, Mu1, in a complex with is protector protein. Sigma3. Cell 2002;108:283-95.
110. Engelke M, Mills K, Seitz S, Simon P, Schnölzer M, Gripon P, et al. Characterization of a hepatitis B and hepatitis Delta virus receptor binding site. Hepatology 2006. In press.
111. Chouteau P, Le Seyec J, Cannie I, Nassal M, Guguen-Guillouzo C, Gripon P. A short N-proximal region in the large envelope protein harbors a determinant that contributes to the species specificity of human hepatitis B virus. J Virol 2001;75:11565-72.
112. Sominskaya I, Pushko P, Dreilina D, Kozlovskaya T, Pumpen P. Determination of the minimal length of preS1 epitope recognized by a monoclonal antibody which inhibits attachment of hepatitis B virus to hepatocytes. Med Microbiol Immunol 1992;181:215-26.
113. Maeng CY, Ryu CJ, Gripon P, Guguen-Guillouzo C, Hong HJ. Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1. Virology 2000;270:9-16.
114. Hong HJ, Ryu CJ, Hur H, Kim S, Oh HK, Oh MS et al. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 2004;318:134-41.
115. Barrera A, Guerra B, Notvall L, Lanford RE. Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J Virol 2005;79:9786-98.
116. Ying C, Van Pelt JF, Van Lommel A, Van Ranst M, Leyssen P, De Clercq E et al. Sulphated and sulphonated polymers inhibit the initial interaction of hepatitis B virus with hepatocytes. Antivir Chem Chemother 2002;13:157-64.
117. Zahn A, Allain JP. Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol 2005;86:677-85.
118. Futamura M, Dhanasekaran P, Handa T, Phillips MC, Lund-Katz S, Saito H. Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces. J Biol Chem 2005;280:5414-22.
119. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology 1993;194:137-48.
120. Heermann KH, Waldeck F, Gerlich WH. Interaction between native human serum and the preS2 domain of hepatitis B virus surface antigen. In: Zuckermann AJ editor. Viral Hepatitis and Liver Disase. New York: Alan R. Liss; 1988. p. 697-700.
121. Sureau C, Guerra B, Lee H. The middle hepatitis B virus envelope protein is not necessary for infectivity of hepatitis delta virus. J Virol 1994;68:4063-6.
122. Oess S, Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther 2000;7:750-8.
123. Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P. Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity. J Virol 1998;72:5573-8.
124. Iwarson S, Tabor E, Thomas HC, Goodall A, Waters J, Snoy P et al. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J Med Virol 1985;16:89-96.
125. Ogata N, Cote PJ, Zanetti AR, Miller RH, Shapiro M, Gerin J et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 1999;30:779-86.
126. Shearer MH, Sureau C, Dunbar B, Kennedy RC. Structural characterization of viral neutralizing monoclonal antibodies to hepatitis B surface antigen. Mol Immunol 1998;35:1149-60.
127. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336:325-9.
128. Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002;68:319-27.
129. Mangold CM, Streeck RE. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J Virol 1993;67:4588-97.
130. Mangold CM, Unckell F, Werr M, Streeck RE. Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. Virology 1995;211:535-43.
131. Gilbert RJ, Beales L, Blond D, Simon MN, Lin BY, Chisari FV et al. Hepatitis B small surface antigen particles are octahedral. Proc Natl Acad Sci U S A 2005;102:14783-8.
132. Wallin M, Ekstrom M, Garoff H. Isomerization of the intersubunit disulphide-bond in Env controls retrovirus fusion. EMBO J 2004;23:54-65.
133. Wallin M, Ekstrom M, Garoff H. The fusion-controlling disulfide bond isomerase in retrovirus Env is triggered by protein destabilization. J Virol 2005;79:1678-85.